Improving the glaucoma surgical armamentarium

Article

Positioning the ExPRESS shunt in the glaucoma surgeon's practice

Among the growing plethora of glaucoma surgical procedures, trabeculectomy remains the most commonly performed procedure due to its track record of achieving low target pressures. Although trabeculectomy has been performed for decades the procedure has evolved over time including the introduction of releasable sutures/suture lysis, the use of anti-metabolites and conjunctival flap design making the modern trabeculectomy very effective at lowering IOP with reduced risks. Potential serious complications exist, however, such as early and late postoperative hypotony, reduced vision due to accelerated cataract growth and bleb-associated infections.

Originally the device was intended to be implanted directly under the conjunctiva, however, due to high rates of hypotony and device extrusion it is now implanted under a scleral flap. This is essentially a modification of a trabeculectomy, with the elimination of manually creating an osteium and a peripheral iridectomy.

Given the similarity to a trabeculectomy, the procedure has a short learning curve specifically for those familiar with trabeculectomy surgery. It was also anticipated that the uniform internal lumen diameter of the shunt would yield more consistent reduction in IOP and specifically reduce rates of early hypotony. Further proposed advantages over conventional trabeculectomy include decreased tissue manipulation by excluding the manual creation of an osteium and peripheral iridectomy, which could result in improved IOP lowering over a trabeculectomy.

The procedure of implanting an ExPRESS shunt under a scleral flap has been embraced by many glaucoma surgeons with thousands of devices implanted worldwide. Unfortunately, what is missing in the literature are well-designed prospective randomized controlled trials (RCTs) comparing the device implanted under a scleral flap to a trabeculectomy. Comparative data of this nature would provide conclusive evidence to secure the position of the ExPRESS shunt in the glaucoma surgical armamentarium.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.